Semaglutide and Tirzepatide should not be used in people with type-1 diabetes or in anyone who is taking insulin and sulfonylureas
(2019) in urine but first detects are reported from De Ruyck et al
In its June 4, 2021 announcement the FDA wrote that this once-weekly, self-injected medicine is: for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity. The official prescribing information for Wegovy offers data on two large, long-term placebo-controlled trials
And from what Ive read and heard is that this such a strong appetite suppressant, that while it can help get you to a very lean body comp, if you dont have an appetite you can suffer from REDS and generally poor performance
Moreover, clinical trials in patients with diabetes are affected by many complex factors, such as diet, race, comorbidities, and drug combinations
